Background {#Sec1}
==========

Cathepsin K is a lysosomal cysteine protease predominately expressed in osteoclasts, the cells responsible for bone resorption \[[@CR1]\]. Osteoclasts form extracellular hemivacuoles in close contact with the bone surface \[[@CR2]\] and vesicular transport within the osteoclasts delivers cathepsin K to the hemivacuoles together with protons. While bone mineral calcium hydroxyapatite dissolves in the acidic environment, cathepsin K, which is proteolytically active at the acidic pH present in hemivacuoles \[[@CR3]\], degrades key organic bone matrix proteins, such as type I collagen. Cleavage of type I collagen results in the release of C-terminal and N-terminal telopeptides (CTX-I and NTX-I). Cathepsin K is also expressed in chondrocytes in cartilage, and is able to cleave type II collagen and aggrecan, the main organic components of the cartilage matrix. Cartilage degradation can be assessed by measuring the C-terminal telopeptide of type II collagen (CTX-II). Although cathepsin K is expressed in other tissues, its main physiological role seems to be in bone resorption. This is reflected by the lack of bone resorption and the high bone mass phenotype in cathepsin K-deficient mice \[[@CR4]\] and in pycnodysostosis patients, who lack functional cathepsin K due to various inactivating mutations in the cathepsin K gene \[[@CR5]\].

The key role of cathepsin K in bone resorption makes the protease an attractive therapeutic target in disorders where bone resorption is excessive, e.g. osteoporosis and in joint diseases involving bone, such as osteoarthritis (OA). This has led to the development of several small molecule cathepsin K inhibitors with oral bioavailability and various potencies and levels of cathepsin K selectivity \[[@CR6]\]. Cathepsin K inhibitors with sufficient potency and bioavailability reduced the biochemical biomarkers of bone resorption, NTX-I and CTX-I, which are normally released into serum/urine \[[@CR7]--[@CR9]\]. This anti-resorptive effect translated into increased bone mineral density (BMD) in ovariectomized monkeys \[[@CR10], [@CR11]\] and clinically in post-menopausal women \[[@CR12], [@CR13]\] and, in the case of odanacatib, reduced the incidence of vertebral and hip fractures in postmenopausal women in a Phase III study \[[@CR14]\].

Cathepsin K inhibition could also be a beneficial strategy for OA since reduced subchondral bone density and quality is believed to lead to cartilage damage in OA \[[@CR15], [@CR16]\]. Available data in nonclinical models of joint degeneration show beneficial effects with experimental cathepsin K inhibitors on subchondral bone, cartilage and pain end-points \[[@CR17]--[@CR19]\]. Moreover, several clinical investigations have shown positive effects on cartilage integrity when subchondral bone resorption is suppressed, and a deterioration of cartilage when resorption is increased \[[@CR16], [@CR20]\]. Indeed, bone-acting compounds known to provide beneficial effects on bone, such as strontium ranelate \[[@CR21]\], risedronate \[[@CR22]\] and calcitonin \[[@CR23]\] have also demonstrated efficacy in clinical trials on OA related endpoints, such as joint space narrowing and WOMAC scores. However, either inconsistent efficacy or safety concerns have precluded approval of these agents for clinical use in OA patients.

MIV-711 is a potent and selective cathepsin K inhibitor that is being developed as a disease-modifying treatment for patients with OA, with recent clinical data showing evidence of beneficial effects on joint structure in patients with moderate knee OA \[[@CR24]\]. The present paper summarizes the nonclinical pharmacological profile of MIV-711 in vitro, and in cynomolgus monkeys in vivo by quantification of biomarkers of bone resorption (CTX-I and NTX-I) and cartilage degradation (CTX-II). In order to assess translation to human, the nonclinical pharmacokinetic and pharmacodynamic characteristics of MIV-711 were compared to data generated in a single ascending dose study with MIV-711 in healthy subjects.

Methods {#Sec2}
=======

Compound {#Sec3}
--------

The batches of MIV-711 (previously referred to as MV076159; \[[@CR25]\]) used in nonclinical experiments were synthesized at Medivir (Huddinge, Sweden). In all nonclinical experiments in vivo, MIV-711 was suspended in 1% w/v methyl cellulose (Methocel 4AC premium, Sigma) and given as a suspension via oral gavage. The vehicle (1% w/v methyl cellulose) was administered to control animals. For the clinical study, MIV-711 was synthesized by NCK A/S (Farum, Denmark), and MIV-711 and placebo capsules were manufactured by Galenica AB (Malmö, Sweden).

Pharmacological characterization of MIV-711 in vitro {#Sec4}
----------------------------------------------------

### Enzyme assays {#Sec5}

Recombinant cathepsin K enzymes from all species were expressed in *E. coli*, purified and activated. Human cathepsin F and cathepsin S were expressed in *Baculovirus*, purified and activated. Purified human cathepsins B and H (Athens Research Technology), cathepsin L (Calbiochem), and cathepsin V (R & D Systems) were purchased.

H-*D*-Ala_Leu-Lys-AMC was used as the substrate in assays of cathepsin K from non-rodent species (human, dog, rabbit and guinea pig), and Z-Leu-Arg-AMC was used as the substrate in assays of cathepsin K from rodent species (mouse and rat). For cathepsins S and V the substrate used was Boc-Val-Leu-Lys-AMC, for cathepsins F and L the substrate was H-*D*-Val-Leu-Lys-AMC, for cathepsin B the substrate was Z-Arg-Arg-AMC and for cathepsin H the substrate was H-Arg-AMC. All substrates were obtained from Bachem.

For cathepsin K the buffer was 100 mmol/L sodium phosphate, 5 mmol/L EDTA, 1 mmol/L DTT, 0.1% PEG 4000, pH 6.5. For cathepsin S the buffer was 100 mmol/L sodium phosphate, 100 mmol/L NaCl, 1 mmol/L DTT, 0.1% PEG 4000, pH 6.5. For cathepsin L the buffer was 100 mmol/L sodium acetate, 1 mmol/L EDTA, 1 mmol/L DTT, 0.1% PEG 4000, pH 5.5. For cathepsin B the buffer was 50 mmol/L sodium phosphate, 1 mmol/L EDTA, pH 6.25. For cathepsin F the buffer was 100 mmol/L sodium acetate, 1 mmol/L EDTA, 1 mmol/L DTT, pH 5.5. For cathepsin H the buffer was 100 mmol/L tris--acetate, 1% PEG4000, pH 7.5. For cathepsin V the buffer was 25 mmol/L sodium acetate, 2.5 mmol/L EDTA, pH 5.5.

Assays were carried out in white polystyrene 96-well plates in a final volume of 100 µL. Substrate concentrations were 10--100 µmol/L and enzyme concentrations were 0.1--5 nmol/L. Compounds were added in DMSO in the range of 1 nmol/L--100 µmol/L at a final DMSO concentration of 1%. Plates were read in a Fluoroskan Ascent (Thermo Labsystems, Helsinki, Finland) in kinetic mode, with excitation and emission filters of 390 and 460 nm, respectively. Rates were determined by linear regression of the fluorescence/time data in Excel. Rates were fitted by non-linear regression to either the competitive inhibition equation, with the substrate concentration fixed at the value in the assay and the K~M~ fixed to the value previously determined, or the IC~50~ equation using GraphPad Prism (GraphPad, version 6, San Diego, USA) to obtain K~i~ or IC~50~ values, respectively.

The kinetics of MIV-711 inhibition of human recombinant cathepsin K were measured by progress curve analysis \[[@CR26]\]. Briefly, 100 µmol/L substrate and 0.5 nmol/L cathepsin K were combined in 0.5 mL of buffer in a quartz cuvette and the fluorescence measured continuously in a spectrofluorometer (Hitachi F-4500, Hitachi Scientific Instruments, Woking, UK). Excitation wavelength was 385 nm and emission wavelength was 460 nm and slits were 5 and 10 nm for excitation and emission, respectively. PMT voltage was 700 V and the response time was 0.01 s. Once a linear rate was established, 5 µL MIV-711 (final assay concentration between 10 and 50 nmol/L) or 5 µL DMSO control was added and data collected until a new equilibrium rate was achieved. Data were imported into GraphPad Prism and then fitted to the Morrison equation \[[@CR26]\] to obtain k~obs~. The k~obs~ values were plotted against the inhibitor concentration and fitted to a straight line to obtain k~on~ and k~off~.

MIV-711 was analyzed against \> 70 different ion channels, receptors, transporters and cytochrome P450 (CYP) enzymes at a concentration of 10 µmol/L at PanLabs (Taipei, Taiwan).

### Osteoclast assay {#Sec6}

The effect of MIV-711 on osteoclast-mediated bone resorption was evaluated using a complete kit from Cambrex Bio Science (Walkersville, MD, USA). Briefly, primary osteoclasts were generated from osteoclast precursors by incubation with RANK ligand and M-CSF in 96-well plates coated with human bone fragments, according to the instructions from the provider. After differentiation (minimum of 5 days), osteoclasts were exposed to different fixed concentrations of MIV-711 for 24 h. The resorption activity of the cultures was determined by quantifying CTX-I in the culture supernatants using a commercially available enzyme-linked immunosorbent assay (CrossLaps^®^, Nordic Bioscience Diagnostics A/S, Herlev, Denmark). Controls exposed to medium without inhibitor were set to 100%. CTX-I levels from MIV-711-treated cells were normalized and expressed as % of control. Curves were generated plotting the concentration of MIV-711 versus % of control. The curves were fitted to the Hill (four parameter) equation to generate an IC~50~ value using GraphPad Prism software. The IC~50~ value was defined as the concentration of MIV-711 that reduced CTX-I levels to 50% of control.

Nonclinical pharmacological characterization of MIV-711 in vivo {#Sec7}
---------------------------------------------------------------

All animal studies were conducted according to the provisions of United Kingdom Law, in particular the Animals (Scientific Procedures) Act, 1986.

Monkeys: plasma CTX-I experiments---single dose {#Sec8}
-----------------------------------------------

Eight cynomolgus monkeys (Macaca fascicularis) were used for measuring plasma levels of MIV-711 and CTX-I after a single dose. The animals were healthy young males, approximately 2--4 years old and weighing 3--4 kg. Experiments were performed at Covance Ltd (Harrogate, UK). The monkeys were used over an extended period of time (up to a year) and several cathepsin K inhibitors were evaluated during this time. At least 1 week was allowed for washout in between experiments. This was not believed to affect the results with MIV-711, and vehicle controls were run on a regular basis when appropriate. Each animal received at least one dose of MIV-711 and one dose of vehicle with at least 1 week of washout in between treatments.

In single dose experiments, animals were dosed with vehicle or MIV-711 (3--30 µmol/kg) via oral gavage at a dose volume of 4 mL/kg between 7:30 and 9:00 a.m. Blood samples were collected at baseline, 30 min, 1, 2, 4, 8, 12, 24 and 48 h after dose from the femoral vein and transferred into lithium heparin anticoagulant tubes. The samples were centrifuged and the two aliquots of the resultant plasma were frozen at − 70 °C. All samples were processed and stored within 30 min of collection. The aliquots were used to determine the MIV-711 concentration and CTX-I levels, respectively.

Each animal treated with MIV-711 was also treated with vehicle and sampled in an identical manner either within 2 weeks prior to MIV-711 administration, or after a washout period of between 1 and 2 weeks to enable each animal to serve as its own control in the analysis of the effects of MIV-711 on CTX-I. The area under the curve (AUC) of CTX-I during treatment with MIV-711 was divided by the AUC of CTX-I during treatment with vehicle, thus giving a % CTX-I inhibition value over 24 h. Since the concentration of MIV-711 was measured in each animal it was possible to relate the MIV-711 exposure over 24 h to the % CTX-I inhibition over 24 h in each animal.

Monkeys: plasma CTX-I experiments---multiple doses {#Sec9}
--------------------------------------------------

Repeat dosing experiments were performed in four male monkeys from the group outlined above (Covance). Vehicle or MIV-711 (30 µmol/kg) was given via oral gavage once daily for 5 days between 7:30 and 8:30 a.m. Plasma for CTX-I measurements was collected on Day 1 at baseline, 1, 2, 4, 8 and 12 h after dose, on Days 2, 3 and 4 early in the morning before next dose (i.e. at trough), and on Day 5 at trough, 1, 2, 4, 8, 12 and 24 h after dose.

Monkeys: urine biomarker experiments---multiple doses {#Sec10}
-----------------------------------------------------

Biomarkers such as NTX-I (bone resorption) and CTX-II (cartilage degradation) are typically measured in urine. Additional experiments in which urine was collected were therefore performed. In these experiments, four cynomolgus monkeys (Macaca fascicularis) were used (Aptuit, Edinburgh, UK). The animals were healthy young females weighing 3.5--4 kg. Animals were dosed with vehicle or MIV-711 via oral gavage at a dose volume of 5 mL/kg between 7:30 and 8:30 a.m. Animals first received vehicle via oral gavage for five consecutive days. After a washout period, the animals then received MIV-711 (30 µmol/kg) via oral gavage for five consecutive days.

Urine was collected between 8--12 a.m., 12 a.m.--4 p.m. and 4 p.m.--8 a.m. on Day 1 and Day 5 of respective treatment. Biomarkers were measured in each urine sample, corrected for creatinine, and the mean value of the three samples on Day 1 and Day 5 was calculated. The effect of MIV-711 was evaluated by comparing biomarkers in urine samples collected on Day 1 and Day 5 with respective vehicle sample.

Single ascending dose study in healthy subjects {#Sec11}
-----------------------------------------------

The protocol and informed consent documentation for the clinical study was reviewed and approved by the independent ethics committee specific for the study center. The study was conducted in accordance with the International Conference on Harmonisation and Good Clinical Practice regulations and guidelines. Prior to the study, all subjects signed informed consent forms and volunteer information documents.

Subjects {#Sec12}
--------

Twenty-seven healthy male and female subjects (18 male and 9 female) of any ethnic origin (24 White, 1 Asian, 1 Black, 1 Black/Caribbean White), aged between 19 and 64 years, and with a body mass index (BMI) between 18.0 and 32.0 kg/m^2^, were selected for this study. Inclusion criteria for enrollment followed the standard practice for first-in-man studies.

Study design {#Sec13}
------------

This was a randomized, double-blind, placebo-controlled, sequential, single-ascending dose study conducted at a single site with the objective of evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of MIV-711. Subjects were randomized into 3 groups using a computer-generated pseudo-random permutation procedure. Each group consisted of 9 subjects with at least 3 subjects of each gender per group and subjects participated in 1--2 treatment periods. There was a minimum of 10 days between dose escalations and a minimum of 20 days between dosing occasions for individual subjects. For each subsequent dosing occasion, the decision to escalate the dose to the next level was taken after a thorough review of the safety, tolerability and PK data. In each treatment period, 7 subjects received MIV-711 and 2 received placebo (comprising of 1 subject of each gender). Dosing occurred on the morning of Day 1 following an overnight fast and subjects were kept in the fasted state until approximately 4.5 h after dosing. MIV-711 was given as a combination of 10 or 40 mg hard gelatin capsules, while placebo was given in similar capsules of identical appearance.

Assessments {#Sec14}
-----------

### Safety {#Sec15}

Standard safety assessments were performed throughout the study and included physical examination, vital signs, 12-lead electrocardiogram (ECG), continuous ECG Holter monitoring, hematology, biochemistry, urinalysis and adverse event monitoring.

### PK {#Sec160}

Blood samples were collected at pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, 24, 36 and 48 h post-dose and processed into plasma for the measurement of concentrations of MIV-711. The PK analysis was conducted using WinNonlin Enterprise Version 5.2 (Pharsight Corporation, Mountain View, CA, USA).

### Pharmacodynamic {#Sec16}

Blood samples were collected at pre-dose, 4, 8, 24 and 48 h post-dose and processed into serum for the measurement of CTX-I concentrations.

Bioanalysis of MIV-711 {#Sec17}
----------------------

The quantification of MIV-711 in monkey plasma was performed by taking 10--50 µL of plasma and mixing with 3 volumes of acetonitrile (10 s, Vibrofix). The sample was centrifuged (10 min, 20,000×*g*, 7 °C) and 5 µL of the supernatant was injected onto the liquid chromatography with tandem mass spectrometric detection (LC--MS/MS) system. The lowest concentration of the standard curves and the lower limit of quantification (LLOQ) was 1 nmol/L of MIV-711. The human plasma samples were prepared by protein precipitation for sample extraction followed by LC--MS/MS. The lowest concentration of the standard curves and the LLOQ was 4 nmol/L of MIV-711 using 25 µL of plasma.

Biomarker measurements {#Sec18}
----------------------

The quantification of CTX-I in monkey plasma samples and human serum samples was performed using a commercially available kit (Serum CrossLaps ELISA, IDS Nordic, Herlev, Denmark). The levels of CTX-I in monkey urine samples were measured using a commercially available kit (Urine BETA CrossLaps ELISA, IDS Nordic). The quantification of NTX-I in monkey samples was performed using a commercially available kit (Osteomark NTx Urine, Wampole Laboratories, Inc, Princeton, USA). Urinary levels of CTX-II in monkey samples were measured using a commercially available kit (Urine CrossLaps EIA, IDS Nordic). The concentrations of biomarkers in the urine samples were corrected for creatinine concentrations. The creatinine levels in urine were determined at Swedish University of Agricultural Sciences, using the enzymatic assay (cat no. 8L24-01) on the Abbott system Architect c4000.

Statistical analysis {#Sec19}
--------------------

In the nonclinical studies, two-way ANOVA was used to assess the effects of MIV-711 on plasma CTX-I. Pearson's correlation was used when comparing plasma exposure of MIV-711 with inhibitory effects on CTX-I. Student's unpaired *t* test was used when assessing the effect of MIV-711 on urine biomarkers. In the clinical study, PK parameters were summarized by dose level using descriptive statistics. The dose proportionality for AUC and C~max~ was assessed by using a power model with determination of the linear regression slope with a 95% confidence interval. Change in CTX-I from baseline at 24 h after dose was calculated by dose level and summarized using descriptive statistics. In addition, the 95% confidence interval for the difference between each MIV-711 group and the placebo group for these variables was calculated by dose level. Pearson's correlation was used when comparing plasma exposure of MIV-711 with inhibitory effects on CTX-I. A time-matched and placebo-corrected approach was used to evaluate the effects of MIV-711 on the QTcF interval from the Holter ECG recordings. The change-from-baseline QTcF at post-dose time points was analyzed using an ANCOVA model including the treatment, time (categorical), and treatment-by-time interaction as fixed effects, baseline QTcF as a covariate, and subject as random effect. A *p* value \< 0.05 was considered statistically significant. Data are expressed as mean ± SEM.

Results {#Sec20}
=======

Pharmacological characterization of MIV-711 in vitro {#Sec21}
----------------------------------------------------

### Inhibition of human cathepsin K and related proteases {#Sec22}

MIV-711 had a mean K~i~ (dissociation constant) value of 0.98 nmol/L for human cathepsin K (Table [1](#Tab1){ref-type="table"}). Selectivity was more than 1300-fold versus the other human cathepsins tested. The catalytically active forms of human and cynomolgus monkey cathepsin K have identical amino acid sequences and there are no known post-translational modifications in the active forms \[[@CR27]\]. Therefore, the catalytically active forms of the human and cynomolgus cathepsin K enzyme are regarded as identical. MIV-711 was also a potent inhibitor of dog, guinea pig and rabbit cathepsin K (Table [1](#Tab1){ref-type="table"}). In contrast, MIV-711 was found to be a substantially less potent inhibitor of rat and mouse cathepsin K enzymes, with IC~50~ values of 240 and 1000 nmol/L respectively.Table 1Potency of MIV-711 against various cathepsin enzymesSpeciesRecombinant enzymeK~i~ (nmol/L)95% CI (nmol/L)nHumanCathepsin K0.980.88--1.0940Cathepsin B13001Cathepsin L17001500--190039Cathepsin F28001Cathepsin V40001Cathepsin H\> 10,0001Cathepsin S15,70012,500--19,80039DogCathepsin K1.50.75--2.94RabbitCathepsin K3.3^a^0.9--124Guinea pigCathepsin K9.88.1--122RatCathepsin K240^a^180--3203MouseCathepsin K1000^a^680--15003K~i~ values are geometric means. 95% CI---geometric 95% confidence interval^a^IC~50~

The k~on~ and k~off~ rates that characterize the binding of MIV-711 to human recombinant cathepsin K were evaluated in an isolated enzyme assay in vitro. The k~on~ rate of MIV-711 to human cathepsin K was 4.6 × 10^6^ M^−1^s^−1^ and the k~off~ rate was 8 × 10^−3^ s^−1^. The k~off~ rate translates to a residence time of about 90 s. From these experiments, the K~i~ value for MIV-711 was 1.7 nmol/L, consistent with the value of 0.98 nmol/L obtained using the equilibrium method above.

No significant responses (more than 50% inhibition) were recorded when MIV-711 was tested against a broad panel of \> 70 different ion channels, receptors, transporters and CYP enzymes at a concentration of 10 µmol/L.

### Inhibition of osteoclast-mediated bone resorption {#Sec23}

The inhibition of bone resorption in vitro by MIV-711 was studied using differentiated human osteoclasts incubated together with human bone fragments. MIV-711 inhibited human osteoclast activity in a concentration-dependent manner with a geometric mean IC~50~ value of 43 nmol/L (Fig. [1](#Fig1){ref-type="fig"}). The results are consistent with a previous study, in which the IC~50~ value of MIV-711 in a bone resorption assay using differentiated human osteoclasts incubated together with bovine bone slices was 37 nmol/L \[[@CR25]\] (note: MIV-711 was referred to as MV076159 in that publication).Fig. 1Effect of MIV-711 on human osteoclast-mediated bone resorption using human bone fragments. Control cells exposed to medium without inhibitor were set to 100%. CTX-I levels from MIV-711-treated cells were normalized and expressed as % of control. Data are from two osteoclast preparations with each preparation measured in triplicate (n = 6). The data were fitted to the Hill equation. Mean ± SEM

Pharmacological characterization of MIV-711 in cynomolgus monkeys in vivo {#Sec24}
-------------------------------------------------------------------------

### Effect of single oral doses of MIV-711 on plasma CTX-I levels {#Sec25}

Healthy, male cynomolgus monkeys were treated with vehicle or MIV-711 at doses of 3, 10 or 30 µmol/kg by oral gavage. The results, shown in Fig. [2](#Fig2){ref-type="fig"}a and Table [2](#Tab2){ref-type="table"}, demonstrate that the administration of increasing doses of MIV-711 resulted in a dose-proportional increase in plasma levels of MIV-711. T~max~ ranged between 1 and 3 h and t~1/2~ ranged between 2 and 4 h. The C~max~ reached with the highest dose was approximately 1 µmol/L. At 24 h post-dose, MIV-711 was no longer detectable (\< LLOQ of 1 nmol/L) in the plasma of animals in the lowest dose group, but it was detectable in some animals in the intermediate dose group, while the plasma concentration of MIV-711 was approximately 10 nmol/L in the highest dose group.Fig. 2**a** MIV-711 concentrations in monkey plasma at various time points after a single dose. **b** Plasma CTX-I levels measured in the same samples as in **a**. **c** Relationship between MIV-711 exposure (AUC~0--24h~) and % inhibition of plasma CTX-I over 24 h. Mean ± SEM Table 2Pharmacokinetic parameters in monkey following single oral doses of MIV-711Dose (µmol/kg)C~max~ (µmol/L)AUC~0--t~ (µmol/L × h)AUC~inf~ (µmol/L × h)t½ (h)t~max~^a^ (h)C~max~/dosen30.102 (65)0.400 (60)0.409 (62)2.1 (16)2.0 (2.0--2.0)0.034 (65)4100.164 (41)0.881 (52)0.932 (46)3.1 (52)2.0 (0.50--4.0)0.016 (41)9300.923 (56)6.21 (62)6.28 (62)3.4 (30)2.0 (1.0--4.0)0.031 (56)11Data are presented as geometric mean (CV%)^a^Median (min--max)

Corresponding plasma CTX-I levels are shown in Fig. [2](#Fig2){ref-type="fig"}b. In the vehicle-treated animals, the normal diurnal rhythm in bone resorption was observed, with plasma CTX-I levels being 47% lower than baseline at 8 h post-dose but having returned to baseline levels at 24 h post dose (Fig. [2](#Fig2){ref-type="fig"}b). MIV-711 reduced plasma CTX-I levels in a dose-dependent manner. The highest dose of MIV-711 reduced CTX-I levels by 57% compared to baseline at 24 h post-dose. This CTX-I lowering effect was statistically significant relative to the vehicle groups at all time points between 2 and 24 h post-dose (*p* \< 0.05). The effect of the mid-dose MIV-711 (10 µmol/kg, p.o.) was statistically significant versus vehicle between 8 and 24 h post-dose (*p* \< 0.05). CTX-I levels after treatment with the low dose MIV-711 (3 µmol/kg, p.o.) did not differ significantly vs. vehicle (*p* \> 0.05). The decreased CTX-I levels were approaching baseline levels in all dose groups at 48 h post dose, indicating that the pharmacological effect of a single dose was fully reversible.

The % CTX-I inhibition over 24 h versus the MIV-711 exposure over 24 h for each individual animal is shown in Fig. [2](#Fig2){ref-type="fig"}c. There was a highly significant correlation between plasma exposure of MIV-711 and effects on bone resorption (*p* \< 0.0001, Pearson correlation, r^2^ = 0.71).

### Effect of repeated oral doses of MIV-711 on plasma CTX-I levels {#Sec26}

Repeat oral dosing with vehicle or MIV-711 (30 µmol/kg, p.o.) once daily in the morning for 5 days resulted in similar reductions in plasma levels of CTX-I on Day 5 as on Day 1 (Fig. [3](#Fig3){ref-type="fig"}). On Day 1, the maximum effect of MIV-711 on plasma CTX-I levels was observed at 12 h post dose (76% reduction from baseline), while on Day 5 the maximal effects were 67% lower than the initial baseline before the first dose. The trough levels of CTX-I in plasma were 38% lower than baseline on Day 5 (compared to 48% after the first dose on Day 1). The trough concentrations of CTX-I in plasma were statistically significantly reduced on each day after MIV-711 treatment compared to the vehicle control (*p* \< 0.05).Fig. 3Plasma CTX-I concentrations in response to repeat oral dosing once daily for 5 days with vehicle or MIV-711 (30 µmol/kg). Mean ± SEM, n = 4

### Effect of repeated oral doses of MIV-711 on urine CTX-I, NTX-I and CTX-II levels {#Sec27}

The effect of MIV-711 on creatinine-corrected levels of CTX-I, NTX-I and CTX-II in urine are shown in Fig. [4](#Fig4){ref-type="fig"}. NTX-I and CTX-II levels did not change after 5-day treatment with vehicle, whereas CTX-I levels were numerically lower on Day 5 compared to Day 1 (*p *\> 0.05). A single dose of MIV-711 immediately reduced urinary CTX-I and NTX-I levels compared to vehicle while CTX-II levels were unaffected. Repeated dosing with MIV-711 for 5 days reduced urinary CTX-I, NTX-I and CTX-II levels by 93% (*p* \< 0.05), 71% (*p* \< 0.05) and 71% (*p* \< 0.05) compared to vehicle, respectively.Fig. 4Urine biomarker concentrations in response to single or repeat oral dosing once daily for 5 days with vehicle or MIV-711 (30 µmol/kg). Biomarkers in the graph were measured in urine samples collected between 0--4, 4--8 and 8--24 h after dose on Day 1 and Day 5 of vehicle and MIV-711 treatment. The mean value of the concentrations measured in the three samples collected was calculated. Mean ± SEM, n = 4. \**p *\< 0.05 versus corresponding vehicle

Single ascending doses of MIV-711 in healthy subjects {#Sec28}
-----------------------------------------------------

In this study, 27 subjects participated and received either MIV-711 or placebo on two separate occasions with a minimum interval between doses of 20 days.

Safety {#Sec29}
------

MIV-711 was safe and well-tolerated when given as single ascending doses to healthy subjects. There were no serious adverse events and no subjects discontinued the study. There were no apparent dose-dependent trends in clinical laboratory data, vital signs, and ECG parameters. Holter ECG monitoring demonstrated that there was no clinically relevant effect on the QTcF interval. After administration of the maximum dose of 600 mg, the upper confidence interval of the projected QTcF effect at the highest observed plasma levels was below 10 ms. Adverse events were reported by 5/10 (50%) placebo-treated subjects, and by 11/35 (31%) MIV-711-treated subjects. In placebo-treated subjects, 2/10 (20%) of the reported adverse events (one mild, one moderate) were considered possibly related to treatment (one headache, one rash) while in MIV-711-treated subjects, 6/35 (17%) of the reported adverse events (all mild) were considered possibly related to treatment (two hot flush, one acne, one rash, one cough, one headache).

Pharmacokinetics {#Sec30}
----------------

Figure [5](#Fig5){ref-type="fig"}a and Table [3](#Tab3){ref-type="table"} demonstrate that the systemic exposure of MIV-711 was dose-proportional over the single dose range of 100--600 mg, and supra-proportional between 20 and 100 mg. The slope for dose proportionality was 1.12 for AUC~0--inf~ (95% CI 1.05--1.19) and 1.14 for C~max~ (95% CI 1.01--1.26) even when including the 20 mg group. MIV-711 was rapidly absorbed with a median t~max~ of 1 h and was eliminated in a biphasic manner with a mean terminal t~1/2~ of 3.4--8.3 h over the 20--600 mg dose range. MIV-711 was extensively metabolised with less than 1% excreted renally unchanged (*data not shown*).Fig. 5**a** MIV-711 concentrations in human plasma at various time points after a single dose. **b** CTX-I levels were measured in serum at various time points after a single dose. **c** Relationship between MIV-711 exposure (AUC~0--24h~) and % inhibition of serum CTX-I at 24 h post-dose. **d** Exposure-efficacy comparison between monkey and human. Grouped data are expressed as Mean ± SEM, n = 7--10 Table 3Pharmacokinetic parameters in human following single oral doses of MIV-711Dose (mg)C~max~ (µmol/L)AUC~0--t~ (µmol/L × h)AUC~inf~ (µmol/L × h)t½ (h)t~max~^a^ (h)C~max~/dosen200.033 (36)0.128 (36)0.158 (32)3.4 (13)1.0 (0.50--2.0)0.12 (26)71000.293 (35)1.13 (38)1.17 (37)3.7 (15)1.0 (1.0--2.2)0.21 (23)72000.756 (43)2.45 (36)2.51 (35)5.0 (16)1.0 (0.50--1.0)0.27 (36)74001.18 (43)4.62 (33)4.75 (32)6.5 (44)1.0 (1.0--1.5)0.23 (37)76001.39 (37)6.75 (30)6.89 (30)8.3 (34)1.0 (1.0--3.0)0.17 (38)7Data are presented as geometric mean (CV%)^a^Median (min--max)

Pharmacodynamics {#Sec31}
----------------

Following administration of placebo, a diurnal variation in serum CTX-I levels was evident, similar to previous studies \[[@CR28]\], with levels steadily declining from around 8:45 a.m. until 4:45 p.m. (8 h post-dose administration), when the lowest levels were observed (Fig. [5](#Fig5){ref-type="fig"}b). CTX-I levels returned to baseline over the next 16 h. MIV-711 treatment reduced nadir CTX-I levels further, and CTX-I levels at 24 h post dose were decreased in a dose-dependent manner (Fig. [5](#Fig5){ref-type="fig"}b). The effect of MIV-711 at 24 h ranged from 20% inhibition versus baseline (20 mg dose) to 79% inhibition versus baseline (600 mg dose). When compared to placebo, the reduction in serum CTX-I levels at 24 h post-dose achieved statistical significance at all dose levels. At 48 h post-dose, CTX-I levels were returning towards baseline levels but were still somewhat reduced in subjects receiving 200--600 mg MIV-711. Figure [5](#Fig5){ref-type="fig"}c demonstrates that increased exposure of MIV-711 in humans reduces CTX-I levels in an exposure-dependent manner. The exposure-effect relationship with MIV-711 was similar when comparing monkey data with human data, the free fraction of MIV-711 being similar in human and monkey (Fig. [5](#Fig5){ref-type="fig"}d). There were highly significant correlations between plasma exposure of MIV-711 and the effects on this biomarker of bone resorption (human: *p *\< 0.0001, r^2^ = 0.58; monkey: *p* = 0.0007, r^2^ = 0.39). The exposures required for 50% reduction of CTX-I at 24 h post dose were 1.3 and 1.5 µmol/L × h for human and monkey, respectively.

Discussion {#Sec32}
==========

Osteoarthritis is a disease characterized by cartilage degradation and increased turnover of bone. Treatments for patients with OA are currently limited to managing the symptoms of the disease. As cathepsin K is the principal protease responsible for the degradation of collagen in both bone and cartilage, cathepsin K inhibition represents an attractive approach to modify the course of the disease. The present paper summarizes the nonclinical pharmacological profile of the cathepsin K inhibitor MIV-711 in vitro and in vivo, and translation of PK profile and pharmacodynamic effects to human in a single ascending dose study with MIV-711 in healthy subjects as the first step towards the selection of the MIV-711 doses to be used in a proof of concept study in OA patients.

MIV-711 displayed high potency against recombinant human cathepsin K enzyme (K~i~: 0.98 nmol/L) and inhibited human osteoclast-mediated bone resorption with an IC~50~ of 43 nmol/L. The observation that concentrations of MIV-711, which has a pKa value of 7.15, need to be around 50-fold higher than the K~i~ value to show effects on bone resorption in vitro is consistent with previous data \[[@CR25]\].

In monkeys, MIV-711 reduced plasma CTX-I concentrations in a dose-dependent manner after oral administration with a highly significant exposure-effect correlation. Interestingly, MIV-711 reduced plasma CTX-I levels by over 50% at 24 h post-dose despite plasma levels of MIV-711 being very low at this time point (mostly \< 10 nmol/L). This suggests a prolonged inhibitory effect of MIV-711 on bone resorption in vivo at relatively low plasma concentrations (AUC~0--24h~: 1.5 µmol × h/L for 50% reduction). The prolonged effect is most likely not due to a long residence time of MIV-711 to the cathepsin K enzyme since the off rate was found to be relatively rapid. Fuller et al. \[[@CR25]\] previously demonstrated that non-acidic (MIV-711) and acidic (odanacatib) cathepsin K inhibitors had similar anti-resorptive potencies in an in vitro assay of human osteoclast-mediated bone resorption, and had similar rapid off-rates from the human cathepsin K enzyme. However, the inhibitory effect MIV-711 on osteoclast function lasted for a significantly longer time than odanacatib after washout, although the effects were fully reversible in both cases. This advantage for non-acidic inhibitors like MIV-711 was attributed to its positive charge in the acidic hemivacuoles, which results in reduced permeation out of the hemivacuole and thereby a longer residence time. The current paper extends these findings by demonstrating that the relatively long-lasting pharmacological effect of MIV-711 in vitro is also observed in vivo.

Repeat dosing of MIV-711 to monkeys also decreased urinary levels of CTX-I and NTX-I. This is to be expected in response to successful target engagement, since cathepsin K is known to generate these telopeptide crosslinks directly from type I collagen via enzymatic cleavage \[[@CR29], [@CR30]\]. MIV-711 reduced urinary NTX-I levels in monkeys by 71%, which is comparable to other cathepsin K inhibitors that have been investigated in clinical studies \[[@CR9], [@CR12], [@CR13]\]. An approximate 70% reduction of urine NTX-I seemed to be the maximal effect that could be attained through cathepsin K inhibition. Presumably, urinary NTX-I can be produced from other tissues besides bone through a cathepsin K-independent manner. By contrast, urinary CTX-I levels were reduced by 93%. This profile of effects on biomarkers, with almost complete reduction of CTX-I and 60--70% reduction of NTX-I, has been shown in humans with other cathepsin K inhibitors in postmenopausal women including MIV-711 \[[@CR9], [@CR13], [@CR31]\]. Doses of cathepsin K inhibitors that have provided these degrees of urinary NTX-1 and CTX-I reductions have also significantly improved bone mineral density in humans \[[@CR12], [@CR13]\]. Urinary levels of CTX-I were reduced much more in monkeys in response to MIV-711 treatment compared to plasma levels of CTX-I. This is similar to human data reported by others \[[@CR9], [@CR13]\]. The reason for this is unclear, but may reflect cathepsin K-independent CTX-I-like immunoreactivity which appears to be present in plasma but not in urine.

MIV-711 also reduced urinary levels of CTX-II by 71% following repeat dosing to monkeys. CTX-II is a C-terminal telopeptide derived from collagen type II, the main structural component of articular cartilage. Cathepsin K has the ability to cleave collagen type II in vitro and clinical data show up-regulation of cathepsin K expression in the joints of OA patients \[[@CR32], [@CR33]\]. However, the cathepsin K-mediated cleavage sites appear to be mainly located in the triple helix of type II collagen \[[@CR34], [@CR35]\] while the CTX-II epitope is released from cartilage by matrix metalloproteinases \[[@CR36]\]. In clinical studies, the cathepsin K inhibitor ONO-5334 reduced urinary CTX-II by 50% after treatment of postmenopausal women with osteoporosis for 12 months \[[@CR13]\]. Similarly, we have shown that 100 mg MIV-711 once daily reduces urinary CTX-II levels by 55% after treatment of postmenopausal women for 1 month \[[@CR31]\] and by 72% in healthy subjects after 200 mg MIV-711 daily for 7 days \[[@CR37]\]. Interestingly, anti-resorptive therapies, which are not expected to directly affect articular cartilage, such as strontium ranelate, risedronate and calcitonin, also reduce urinary levels of CTX-II in OA patients \[[@CR21]--[@CR23]\]. Hence, the effects of MIV-711 on CTX-II levels may be mediated by cathepsin K engagement directly in cartilage or indirectly by engaging cathepsin K in subchondral bone or both mechanisms could be involved. In the current paper, urinary CTX-II levels were largely unaffected by a single dose of MIV-711, while bone resorption biomarkers were immediately reduced. After treatment with MIV-711 for 5 days, CTX-II levels were also reduced in the monkeys. This apparent delay in CTX-II reduction could suggest an indirect mechanism, but could also be due to differences in the turnover of these biomarkers. Nonetheless, CTX-II is the most frequently used biomarker for assessing cartilage degradation in OA and has been useful for assessing disease burden, predicting progression and has been reduced in several clinical trials of drugs that were shown to have a beneficial effect on structural endpoints \[[@CR38], [@CR39]\]. The CTX-II data suggests that MIV-711 may be useful in reducing subchondral bone turnover and attenuating cartilage disease progression in OA patients. Indeed, MIV-711 has demonstrated protective effects on subchondral bone and articular cartilage in nonclinical disease models \[[@CR40]\] at exposures that are in the same range as reported in this study. Additionally, recent clinical data from a Phase II study with MIV-711 in knee OA patients, given once daily for 6 months, demonstrated benefit on joint structure, with significantly lower increases in bone area and cartilage thinning in the diseased knee, as assessed by magnetic resonance imaging (MRI), compared to patients who received placebo \[[@CR24]\].

The prolonged pharmacodynamic effect on plasma CTX-I, and the exposure-effect correlation observed in monkey appeared to translate well to humans where relatively low plasma concentrations of MIV-711 were sufficient for a given anti-resorptive efficacy. In humans, more than 50% reduction of serum CTX-I was attained at 24 h after single doses of 100 mg and higher; a time point when plasma concentrations of MIV-711 were close to, or below, LLOQ (\< 4 nmol/L). For instance, 100 mg MIV-711 evoked a 54% reduction of CTX-I at 24 h post-dose, a time point when the plasma levels were mostly \< 4 nmol/L. The AUC~0--24h~ at 100 mg MIV-711 was 1.1 µmol × h/L (Table [3](#Tab3){ref-type="table"}) which is consistent with nonclinical experiments, in which an AUC~0--24h~ of 1.5 µmol × h/L was required for 50% CTX-I reduction at trough. In contrast to MIV-711, the trough plasma IC~50~ for odanacatib in human when given at a weekly dose of 50 mg (the dosing regimen used in the Phase III studies), has been reported to be approximately 50--60 nmol/L \[[@CR8], [@CR41]\] with a mean plasma AUC~0--24h~ in the range of 6--7 µmol × h/L \[[@CR41], [@CR42]\]. Taken together, this suggests that MIV-711 can produce consistent anti-resorptive effects at low circulating plasma levels indicating a sustained level of inhibition of osteoclast-derived cathepsin K. A compound producing a high level of efficacy at low circulating concentrations may be important when targeting cathepsin K. The cathepsin K inhibitor balicatib failed in clinical development due to rash and morphea-like skin reactions \[[@CR43]\]. This has been claimed to be due to balicatib's lysosomotropic properties \[[@CR44]\], the rationale being that non-acidic inhibitors like balicatib would accumulate in acidic organelles and lose selectivity towards other cathepsins. However, the cathepsin K inhibitor ONO-5334 is relatively non-selective for cathepsin K when compared to balicatib, odanacatib and MIV-711 \[[@CR45]\], but appears to be well-tolerated when given to post-menopausal osteoporotic women for 24 months \[[@CR46]\]. This speaks against possible loss of cathepsin K selectivity being associated with side effects. Furthermore, it has been reported that odanacatib, which is acidic and non-lysosomotropic, was associated with increased risk of stroke and morphea-like skin lesions in a large phase III trial \[[@CR14], [@CR47]\]. Cathepsin K is present in other tissues like lung and skin. However, life-long deficiency of cathepsin K in pycnodysostosis patients is not associated with any obvious disorders in these organs to our knowledge. It is currently unknown if the side effects of these cathepsin K inhibitors are due to cathepsin K targeting, to their selectivity profile for other cathepsin subtypes, their chemical structure (balicatib and odanacatib have the same electrophilic groups designed to form a covalent bond to the active site cysteine) or to other unknown pharmacological effects. Nevertheless, the diverse nature of the adverse events associated with cathepsin K inhibitors may suggest that these are largely related to their effects on targets other than cathepsins. MIV-711 was well tolerated in the current study and in longer studies in postmenopausal women for up to 28 days, as well as in OA patients for up to 6 months \[[@CR24], [@CR31]\]. The most common adverse effects in healthy subjects after dosing with 100 mg MIV-711 once daily for 28 days included skin reactions at ECG electrode sites, headache and gastrointestinal symptoms with comparable incidence after active drug or placebo \[[@CR31]\]. In OA patients, the most common adverse effects after treatment with MIV-711 at 100 or 200 mg once daily for 6 months were infrequent musculoskeletal symptoms, infections and rashes \[[@CR24]\].

The results demonstrate that MIV-711 is a highly potent, selective, and rapidly reversible inhibitor of human cathepsin K. MIV-711 inhibited the resorptive capacity of human osteoclasts in vitro and also reduced bone resorption in vivo in cynomolgus monkey when given once daily via oral gavage. The anti-resorptive duration in vivo in monkeys outlasted the pharmacokinetics of MIV-711 since a maintained effect (up to 57% reduction) on plasma CTX-I at 24 h post-dose was present despite plasma levels of MIV-711 being at, or below, the level of detection at this time point. MIV-711 also significantly reduced urinary levels of bone resorption biomarkers (CTX-I and NTX-I) as well as CTX-II, a biomarker of cartilage degradation after repeated 5-day dosing. This profile was confirmed in humans where single doses of MIV-711 dose-dependently reduced CTX-I levels by up to 79% at 24 h post dose when concentrations of MIV-711 are minimal. There were no safety or tolerability concerns after single doses and no meaningful effects on the QTcF interval.

Conclusions {#Sec33}
===========

MIV-711 is a potent and selective cathepsin K inhibitor with dose-dependent effects on biomarkers of bone and cartilage degradation in monkey and human. Taken together, MIV-711 shows promise for the treatment of bone and cartilage related disorders in humans such as OA.
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